Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
119.30 EUR | -1.89% |
|
+0.25% | +15.27% |
07-11 | BIOMERIEUX : Attractiveness reinforced | ![]() |
06-16 | BioMérieux S.A. acquired Key Assets of Day Zero Diagnostics Inc. | CI |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 9.93 | 11.72 | 7.83 | 6.81 | 7.23 | |||||
Return on Total Capital | 13.18 | 15.17 | 9.86 | 8.45 | 8.89 | |||||
Return On Equity % | 17.01 | 21.15 | 12.95 | 8.73 | 10.68 | |||||
Return on Common Equity | 17.45 | 21.64 | 13.47 | 9.72 | 10.86 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 56.24 | 58.16 | 55.97 | 55.99 | 55.66 | |||||
SG&A Margin | 25.31 | 24.24 | 26.6 | 27.77 | 27.58 | |||||
EBITDA Margin % | 25.54 | 29.74 | 22.68 | 23.34 | 23.82 | |||||
EBITA Margin % | 21.19 | 25.48 | 19.38 | 18.82 | 18.59 | |||||
EBIT Margin % | 19.64 | 23.72 | 17.08 | 15.48 | 16.03 | |||||
Income From Continuing Operations Margin % | 12.91 | 17.72 | 12.28 | 8.78 | 10.68 | |||||
Net Income Margin % | 12.97 | 17.8 | 12.6 | 9.73 | 10.86 | |||||
Net Avail. For Common Margin % | 12.97 | 17.8 | 12.6 | 9.73 | 10.86 | |||||
Normalized Net Income Margin | 11.77 | 14.71 | 10.89 | 10.65 | 10.05 | |||||
Levered Free Cash Flow Margin | 9.08 | 11.7 | 4.67 | 4.34 | 7.48 | |||||
Unlevered Free Cash Flow Margin | 9.56 | 11.87 | 4.75 | 4.41 | 7.73 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.81 | 0.79 | 0.73 | 0.7 | 0.72 | |||||
Fixed Assets Turnover | 2.98 | 2.94 | 2.77 | 2.56 | 2.49 | |||||
Receivables Turnover (Average Receivables) | 5.42 | 5.68 | 5.39 | 5 | 5.23 | |||||
Inventory Turnover (Average Inventory) | 2.63 | 2.4 | 2.33 | 1.97 | 1.81 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.8 | 2.31 | 1.96 | 2.03 | 2.2 | |||||
Quick Ratio | 1.16 | 1.57 | 1.25 | 1.12 | 1.22 | |||||
Operating Cash Flow to Current Liabilities | 0.63 | 0.85 | 0.42 | 0.41 | 0.59 | |||||
Days Sales Outstanding (Average Receivables) | 67.49 | 64.24 | 67.66 | 72.94 | 69.93 | |||||
Days Outstanding Inventory (Average Inventory) | 139.02 | 152.01 | 156.73 | 185.69 | 201.79 | |||||
Average Days Payable Outstanding | 54.32 | 54.15 | 54.71 | 54.53 | 51.95 | |||||
Cash Conversion Cycle (Average Days) | 152.2 | 162.1 | 169.68 | 204.1 | 219.77 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 19.4 | 14.57 | 13.87 | 13.83 | 11.65 | |||||
Total Debt / Total Capital | 16.25 | 12.72 | 12.18 | 12.15 | 10.44 | |||||
LT Debt/Equity | 14.2 | 11.43 | 8.74 | 9.47 | 8.29 | |||||
Long-Term Debt / Total Capital | 11.89 | 9.98 | 7.68 | 8.32 | 7.43 | |||||
Total Liabilities / Total Assets | 36.83 | 31.24 | 29.76 | 28.65 | 27.02 | |||||
EBIT / Interest Expense | 25.41 | 88.02 | 149.51 | 129.32 | 39.87 | |||||
EBITDA / Interest Expense | 34.08 | 113.4 | 205.59 | 201.66 | 61.38 | |||||
(EBITDA - Capex) / Interest Expense | 22.56 | 81.52 | 135.66 | 124.77 | 39.77 | |||||
Total Debt / EBITDA | 0.59 | 0.45 | 0.6 | 0.58 | 0.5 | |||||
Net Debt / EBITDA | 0.11 | -0.33 | -0.06 | 0.19 | 0.04 | |||||
Total Debt / (EBITDA - Capex) | 0.89 | 0.62 | 0.91 | 0.94 | 0.77 | |||||
Net Debt / (EBITDA - Capex) | 0.17 | -0.46 | -0.08 | 0.3 | 0.06 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 16.58 | 8.27 | 6.31 | 2.38 | 8.31 | |||||
Gross Profit, 1 Yr. Growth % | 19.58 | 11.97 | 0.39 | 2.42 | 7.68 | |||||
EBITDA, 1 Yr. Growth % | 44.66 | 26.05 | -19.01 | 0.61 | 10.54 | |||||
EBITA, 1 Yr. Growth % | 53.2 | 30.19 | -17.57 | -0.62 | 6.99 | |||||
EBIT, 1 Yr. Growth % | 57.7 | 30.78 | -24.65 | -7.18 | 12.11 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 49.31 | 48.55 | -26.35 | -26.74 | 31.69 | |||||
Net Income, 1 Yr. Growth % | 48.24 | 48.64 | -24.74 | -20.96 | 20.86 | |||||
Normalized Net Income, 1 Yr. Growth % | 58.55 | 35.34 | -22.51 | 0.14 | 2.17 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 48.26 | 48.39 | -24.51 | -21.2 | 20.93 | |||||
Accounts Receivable, 1 Yr. Growth % | 8.3 | -1.22 | 25.31 | -1.55 | 8.74 | |||||
Inventory, 1 Yr. Growth % | 9.54 | 17.11 | 18.9 | 23.24 | 14.18 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 4.23 | 14.62 | 11.85 | 9.94 | 12.59 | |||||
Total Assets, 1 Yr. Growth % | 3.86 | 17.54 | 12.63 | 1.4 | 9.71 | |||||
Tangible Book Value, 1 Yr. Growth % | 31.45 | 48.94 | 6.67 | 16.53 | 18.13 | |||||
Common Equity, 1 Yr. Growth % | 10.31 | 28.46 | 15.81 | 4.11 | 12.06 | |||||
Cash From Operations, 1 Yr. Growth % | 42.88 | 39.17 | -42.39 | -6.25 | 49.82 | |||||
Capital Expenditures, 1 Yr. Growth % | 1.83 | 4.54 | -1.17 | 18 | 2.22 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 178.45 | 39.73 | -56.88 | -22.77 | 95.59 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 161.02 | 34.34 | -56.85 | -22.4 | 89.85 | |||||
Dividend Per Share, 1 Yr. Growth % | 226.32 | 37.1 | 0 | 0 | 5.88 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 13.48 | 12.35 | 7.29 | 4.33 | 5.3 | |||||
Gross Profit, 2 Yr. CAGR % | 16.04 | 15.71 | 7.02 | 1.4 | 5.02 | |||||
EBITDA, 2 Yr. CAGR % | 23.86 | 35.04 | 1.09 | -7.62 | 5.46 | |||||
EBITA, 2 Yr. CAGR % | 27.73 | 41.22 | 2.6 | -9.49 | 3.11 | |||||
EBIT, 2 Yr. CAGR % | 29.81 | 43.61 | 0.04 | -16.37 | 2.01 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 25.57 | 48.93 | 4.6 | -26.54 | -1.77 | |||||
Net Income, 2 Yr. CAGR % | 25.56 | 48.44 | 5.77 | -22.87 | -2.26 | |||||
Normalized Net Income, 2 Yr. CAGR % | 31.5 | 46.49 | 3.2 | -11.91 | 1.15 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 25.36 | 48.32 | 5.84 | -22.87 | -2.38 | |||||
Accounts Receivable, 2 Yr. CAGR % | 10.26 | 3.43 | 11.26 | 11.07 | 3.47 | |||||
Inventory, 2 Yr. CAGR % | 13.75 | 13.26 | 16.64 | 21.05 | 18.62 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 9.02 | 9.3 | 13.22 | 10.89 | 11.25 | |||||
Total Assets, 2 Yr. CAGR % | 5.87 | 10.49 | 14.91 | 6.87 | 5.47 | |||||
Tangible Book Value, 2 Yr. CAGR % | 30.99 | 39.93 | 25.71 | 11.49 | 17.33 | |||||
Common Equity, 2 Yr. CAGR % | 12.29 | 19.04 | 21.76 | 9.8 | 8.01 | |||||
Cash From Operations, 2 Yr. CAGR % | 20.74 | 41.01 | -9.71 | -26.51 | 18.51 | |||||
Capital Expenditures, 2 Yr. CAGR % | 10.71 | 3.18 | 1.64 | 7.99 | 9.82 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 11.64 | 97.07 | -22.96 | -36 | 20.13 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 11.59 | 87.26 | -24.43 | -35.91 | 21.38 | |||||
Dividend Per Share, 2 Yr. CAGR % | 33.1 | 111.51 | 17.09 | 0 | 2.9 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 10.87 | 11.72 | 10.3 | 5.63 | 5.64 | |||||
Gross Profit, 3 Yr. CAGR % | 13.11 | 14.67 | 11.05 | 5.47 | 3.45 | |||||
EBITDA, 3 Yr. CAGR % | 18.8 | 24.59 | 13.92 | 2.5 | -1.92 | |||||
EBITA, 3 Yr. CAGR % | 21.85 | 28.54 | 17.27 | 1.52 | -4.3 | |||||
EBIT, 3 Yr. CAGR % | 22.32 | 30.13 | 16.43 | -2.43 | -7.79 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 19.24 | 32.8 | 17.78 | -7.11 | -10.76 | |||||
Net Income, 3 Yr. CAGR % | 19.31 | 32.83 | 18.37 | -4.02 | -10.41 | |||||
Normalized Net Income, 3 Yr. CAGR % | 23.34 | 32.77 | 19.08 | 2.17 | -7.45 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 19.27 | 32.61 | 18.43 | -4.07 | -10.4 | |||||
Accounts Receivable, 3 Yr. CAGR % | 9.13 | 6.29 | 10.26 | 6.81 | 10.29 | |||||
Inventory, 3 Yr. CAGR % | 12.53 | 14.86 | 14.22 | 18.8 | 18.71 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 14.52 | 10.85 | 10.14 | 12.12 | 11.45 | |||||
Total Assets, 3 Yr. CAGR % | 9.52 | 9.62 | 11.1 | 10.22 | 7.81 | |||||
Tangible Book Value, 3 Yr. CAGR % | 16.63 | 36.72 | 27.6 | 22.57 | 13.66 | |||||
Common Equity, 3 Yr. CAGR % | 11.85 | 17.44 | 17.82 | 15.56 | 10.55 | |||||
Cash From Operations, 3 Yr. CAGR % | 19.53 | 26.59 | 5.21 | -8.57 | -6.82 | |||||
Capital Expenditures, 3 Yr. CAGR % | 14.78 | 8.62 | 1.71 | 6.83 | 6.03 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 33.12 | 20.24 | 18.16 | -17.39 | -8.53 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 31.86 | 18.71 | 14.24 | -18.38 | -7.96 | |||||
Dividend Per Share, 3 Yr. CAGR % | 22.17 | 34.42 | 64.77 | 11.09 | 1.92 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 9.68 | 9.93 | 9.42 | 8.7 | 8.27 | |||||
Gross Profit, 5 Yr. CAGR % | 12.13 | 12.27 | 10.64 | 9.58 | 8.6 | |||||
EBITDA, 5 Yr. CAGR % | 15.72 | 18.01 | 11.37 | 10.56 | 11.48 | |||||
EBITA, 5 Yr. CAGR % | 17.45 | 20.29 | 13.75 | 11.28 | 11.39 | |||||
EBIT, 5 Yr. CAGR % | 18.69 | 21.88 | 12.87 | 9.38 | 10.43 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 29.56 | 27.26 | 13.16 | 4.8 | 9.53 | |||||
Net Income, 5 Yr. CAGR % | 29.63 | 27.4 | 13.7 | 6.87 | 9.64 | |||||
Normalized Net Income, 5 Yr. CAGR % | 20 | 23.64 | 14.85 | 13.02 | 11.56 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 29.58 | 27.3 | 13.7 | 6.76 | 9.62 | |||||
Accounts Receivable, 5 Yr. CAGR % | 6.08 | 4.86 | 9.97 | 8.18 | 7.49 | |||||
Inventory, 5 Yr. CAGR % | 8.78 | 9.43 | 14.15 | 16.75 | 15.96 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 13.25 | 10.77 | 14 | 10.87 | 10.59 | |||||
Total Assets, 5 Yr. CAGR % | 7.21 | 8.8 | 11.65 | 8.46 | 8.82 | |||||
Tangible Book Value, 5 Yr. CAGR % | 19.67 | 25.5 | 20.18 | 25.87 | 23.38 | |||||
Common Equity, 5 Yr. CAGR % | 10.22 | 14.04 | 15.71 | 14.24 | 13.79 | |||||
Cash From Operations, 5 Yr. CAGR % | 13.46 | 19.3 | 6.84 | 2.18 | 10.35 | |||||
Capital Expenditures, 5 Yr. CAGR % | 5.91 | 4.48 | 9.33 | 8.36 | 4.88 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 19.5 | 30.88 | 6.93 | -6.84 | 23.97 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 18.62 | 28.69 | 5.54 | -7.51 | 21.92 | |||||
Dividend Per Share, 5 Yr. CAGR % | 13.22 | 20.59 | 20.11 | 19.42 | 36.49 |
- Stock Market
- Equities
- BIM Stock
- Financials bioMérieux
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition